HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Erratum (v53,p2518) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vozarova de Courten, B. Articles by Tataranni, P. A. Search for Related Content PubMed PubMed Citation Articles by Vozarova de Courten, B. Articles by Tataranni, P. A. Social Bookmarking                What's this?

High Serum Resistin Is Associated With an Increase in Adiposity But Not a Worsening of Insulin Resistance in Pima Indians

¹ Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, Arizona
² Department of Medicine, Division of Endocrinology and Metabolism, Indiana University, School of Medicine, Indianapolis, Indiana

Resistin is an adipokine with putative prodiabetogenic properties. Like other hormones secreted by adipose tissue, resistin is being investigated as a possible etiologic link between excessive adiposity and insulin resistance. Although there is growing evidence that circulating levels of this adipokine are proportional to the degree of adiposity, an effect on insulin resistance in humans remains unproven. To evaluate the relations among resistin, obesity, and insulin resistance, we measured fasting serum resistin levels in 113 nondiabetic (75-g oral glucose tolerance test) Pima Indians (ages 29 ± 7 years, body fat 31 ± 8%, resistin 3.7 ± 1.1 ng/ml [means ± SD]), who were characterized for body composition (assessed by hydrodensitometry or dual-energy X-ray absorptiometry), whole-body insulin sensitivity (M; assessed by hyperinsulinemic clamp), basal hepatic glucose output (BHGO) and hepatic glucose output during low-dosage insulin infusion of a hyperinsulinemic clamp (HGO; a measure of hepatic insulin resistance), and acute insulin secretory response (AIR; assessed by 25-g intravenous glucose tolerance test). Follow-up measurements of M, BHGO, HGO, and AIR were available for 34 subjects who had normal glucose tolerance at baseline and remained nondiabetic at follow-up. The average time to follow-up was 4.5 ± 2.7 years. In cross-sectional analyses, serum resistin levels were positively associated with percent body fat (r = 0.37, P = 0.0001) and 2-h glucose (r = 0.19, P = 0.04), respectively. Serum resistin levels were not associated with fasting glucose and insulin levels, M, BHGO, HGO, or AIR (r = 0.17, 0.12, –0.13, –0.06, –0.03, and –0.04, respectively; all P > 0.05). After adjusting for percent body fat, there was no association between serum resistin levels and 2-h glucose (r = 0.06, P = 0.6). In prospective analyses, high serum resistin levels at baseline were not associated with a decline in M (r = –0.1, P > 0.5). Resistin levels were, however, associated with increases in percent body fat, fasting plasma insulin, and HGO (r = 0.34, 0.36, and 0.37; all P < 0.05) after adjusting for sex, age, and time to follow-up. After additional adjustment for the change in percent body fat, there was no association between baseline serum resistin levels and changes in plasma insulin or HGO (r = 0.26 and 0.23; both P > 0.1). We conclude that in Pima Indians, like other human populations, circulating resistin levels are proportional to the degree of adiposity, but not the degree of insulin resistance. We unexpectedly found that high serum resistin levels do predict future increases in percent body fat. Our data suggest that resistin promotes obesity but not obesity-associated insulin resistance in humans.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I Pantsulaia, G Livshits, S Trofimov, and E Kobyliansky Genetic and environmental determinants of circulating resistin level in a community-based sample Eur. J. Endocrinol., January 1, 2007; 156(1): 129 - 135. [Abstract] [Full Text] [PDF]

				M. M. Haluzik, Z. Lacinova, M. Dolinkova, D. Haluzikova, D. Housa, A. Horinek, Z. Vernerova, T. Kumstyrova, and M. Haluzik Improvement of Insulin Sensitivity after Peroxisome Proliferator-Activated Receptor-{alpha} Agonist Treatment Is Accompanied by Paradoxical Increase of Circulating Resistin Levels Endocrinology, September 1, 2006; 147(9): 4517 - 4524. [Abstract] [Full Text] [PDF]

				M. J. Bahr, J. Ockenga, K. H. W. Boker, M. P. Manns, and U. J. F. Tietge Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E199 - E206. [Abstract] [Full Text] [PDF]

				A. Kunnari, O. Ukkola, M. Paivansalo, and Y. A. Kesaniemi High Plasma Resistin Level Is Associated with Enhanced Highly Sensitive C-Reactive Protein and Leukocytes J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2755 - 2760. [Abstract] [Full Text] [PDF]

				C. Pagano, G. Soardo, C. Pilon, C. Milocco, L. Basan, G. Milan, D. Donnini, D. Faggian, M. Mussap, M. Plebani, et al. Increased Serum Resistin in Nonalcoholic Fatty Liver Disease Is Related to Liver Disease Severity and Not to Insulin Resistance J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1081 - 1086. [Abstract] [Full Text] [PDF]

				F. Haugen, T. Ranheim, N. K. Harsem, E. Lips, A. C. Staff, and C. A. Drevon Increased plasma levels of adipokines in preeclampsia: relationship to placenta and adipose tissue gene expression Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E326 - E333. [Abstract] [Full Text] [PDF]

				M. S. Burnett, J. M. Devaney, R. J. Adenika, R. Lindsay, and B. V. Howard Cross-Sectional Associations of Resistin, Coronary Heart Disease, and Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 64 - 68. [Abstract] [Full Text] [PDF]

				D. Barb, S. G. Wadhwa, J. Kratzsch, A. Gavrila, J. L. Chan, C. J. Williams, A. W. Karchmer, and C. S. Mantzoros Circulating Resistin Levels Are Not Associated with Fat Redistribution, Insulin Resistance, or Metabolic Profile in Patients with the Highly Active Antiretroviral Therapy-Induced Metabolic Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5324 - 5328. [Abstract] [Full Text] [PDF]

				J. R. Berggren, M. W. Hulver, and J. A. Houmard Fat as an endocrine organ: influence of exercise J Appl Physiol, August 1, 2005; 99(2): 757 - 764. [Abstract] [Full Text] [PDF]

				I. Munir, H.-W. Yen, T. Baruth, R. Tarkowski, R. Azziz, D. A. Magoffin, and A. J. Jakimiuk Resistin Stimulation of 17{alpha}-Hydroxylase Activity in Ovarian Theca Cells in Vitro: Relevance to Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4852 - 4857. [Abstract] [Full Text] [PDF]

				M. Gerber, A. Boettner, B. Seidel, A. Lammert, J. Bar, E. Schuster, J. Thiery, W. Kiess, and J. Kratzsch Serum Resistin Levels of Obese and Lean Children and Adolescents: Biochemical Analysis and Clinical Relevance J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4503 - 4509. [Abstract] [Full Text] [PDF]

				J. Verhaeghe, R. van Bree, S. Lambin, and S. Caluwaerts Adipokine Profile and C-Reactive Protein in Pregnancy: Effects of Glucose Challenge Response Versus Body Mass Index Reproductive Sciences, July 1, 2005; 12(5): 330 - 334. [Abstract] [PDF]

				C. Pagano, O. Marin, A. Calcagno, P. Schiappelli, C. Pilon, G. Milan, M. Bertelli, E. Fanin, G. Andrighetto, G. Federspil, et al. Increased Serum Resistin in Adults with Prader-Willi Syndrome Is Related to Obesity and Not to Insulin Resistance J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4335 - 4340. [Abstract] [Full Text] [PDF]

				D. Kamin, C. Hadigan, M. Lehrke, S. Mazza, M. A. Lazar, and S. Grinspoon Resistin Levels in Human Immunodeficiency Virus-Infected Patients with Lipoatrophy Decrease in Response to Rosiglitazone J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3423 - 3426. [Abstract] [Full Text] [PDF]

				P. A. Tataranni and E. Ortega A Burning Question: Does an Adipokine-Induced Activation of the Immune System Mediate the Effect of Overnutrition on Type 2 Diabetes? Diabetes, April 1, 2005; 54(4): 917 - 927. [Abstract] [Full Text] [PDF]

				J. Svensson, H. Herlitz, P.-A. Lundberg, and G. Johannsson Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2290 - 2296. [Abstract] [Full Text] [PDF]

				J. Housova, K. Anderlova, J. Krizova, D. Haluzikova, J. Kremen, T. Kumstyrova, H. Papezova, and M. Haluzik Serum Adiponectin and Resistin Concentrations in Patients with Restrictive and Binge/Purge Form of Anorexia Nervosa and Bulimia Nervosa J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1366 - 1370. [Abstract] [Full Text] [PDF]

				J. H. Lee, J. W. Bullen Jr., V. L. Stoyneva, and C. S. Mantzoros Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E625 - E632. [Abstract] [Full Text] [PDF]

				M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader Resistin Is an Inflammatory Marker of Atherosclerosis in Humans Circulation, February 22, 2005; 111(7): 932 - 939. [Abstract] [Full Text] [PDF]